Sponsor Check › Person
Named as an officer, director or promoter on SEC Form D filings · CA, MA, CT · Jul 16, 2013 → Feb 19, 2021
Data last updated Oct 23, 2026, 5:45 PM ET · Courts (RECAP) last checked: Oct 24, 2026, 2:29 AM ET · SEC enforcement last checked: covered by the index scan as of Oct 24, 2026, 2:50 AM ET
Kush Parmar is listed as an executive officer and director on 40 SEC Form D filings by 17 issuers between Jul 2013 and Dec 2025. Largest by amount reported sold: 5AM Ventures V, L.P. (Menlo Park, CA — pooled investment fund — 2016; $285M reported sold to 80 investors), Rallybio Corp (New Haven, CT — pharmaceuticals — 2020–2024; $145.2M reported sold to 28 investors), Ensoma, Inc. (Boston, MA — biotechnology — 2021–2023; $129M reported sold to 22 investors), Entrada Therapeutics, Inc. (Boston, MA — biotechnology — 2016–2021; $116.2M reported sold to 26 investors), Vor Biopharma Inc. (Cambridge, MA — industry reported as "Other" — 2020; $110.1M reported sold to 33 investors) and 12 more (all listed below).
What this means That is a lot of deals — 17 separate companies raised money with this person listed as executive officer and director, over about 12 years. Across those companies the filings report $1.18B sold in total.
Listed alongside Andrew Schwab (11 shared filings), Albert Seymour (5 shared filings), Mette Kirstine Agger (5 shared filings), Pieter Muntendam (5 shared filings), Tim Shannon (5 shared filings) and 92 others.
What this means These are the other officers, directors or promoters the companies named on the same forms — the team around Kush. Each name links to their own page.
The issuers belong to 2 sponsor groups: Group linked by Anna C. Yaeger (2 issuers, $31.7M reported sold, 2024–2025) and Arvinas (2 issuers, $36M reported sold, 2013–2019).
What this means This person is listed across more than one sponsor team; each group page shows that team's full track record.
Public records searched: federal courts (CourtListener / RECAP), SEC enforcement releases, state securities regulators (AK, AL, AR, AZ, CA, CO, CT, DC, DE, FINRA, FL, GA, HI, ID, IL, KS, KY, LA, MA, MD, ME, MI, MO, MS, MT, NASAA, NC, ND, NH, NM, NV, NY, OH, OK, OR, PA, RI, SC, SD, TN, TX, UT, VT, WA, WI, WV, WY) — none found.
What this means Nothing turned up where we looked (3 sources). That does not prove there is nothing — it means none was found in those sources on that date.
We compared 40 public filings for Kush Parmar and found 17 differences, 1 worth asking the sponsor about: Kush Parmar appears on 5 deals that stopped filing before reaching their target; and more below.
What this means These are differences between the sponsor's own SEC filings — both values, dates and sources are listed in Key records, section 4. Most have ordinary explanations; ask the sponsor.
Community search for Kush Parmar has not run yet — it is joining a line of 43,387 names; searches run around the clock at the hosts' allowed rate. Searched so far: 641 names.
Community comments are quoted as written by their authors. Sources searched: Bing (site:reddit.com / site:biggerpockets.com) and Reddit's own search, plus DuckDuckGo/Brave/BiggerPockets search when they are answering.
Five things investors ask first. Items still in human review are counted, not shown.
None found in sources searched — federal courts (CourtListener / RECAP), checked Oct 24, 2026
Sources searched: CourtListener bulk data (RECAP dockets as of 2026-09-30; recall-first rule 10-24) — federal district + bankruptcy courts State courts: not covered (one-tap state court links under Look further). PACER: not searched. · Last checked Oct 24, 2026, 2:29 AM ET.
State courts: not covered (one-tap state court links under Look further). No state offers a lawful automated statewide source PartnerFacts can use today. Texas (re:SearchTX) terms prohibit storing results in a database open to third parties; New York (WebCivil) and Massachusetts (MassCourts) require a browser check that blocks scripted queries; California has no statewide index (58 county portals; Rule of Court 2.503 grants name-based access case by case); Florida, Utah and Illinois offer paid or partial access whose terms for automated use are unverified. Washington (dw.courts.wa.gov; bulk index reports under a JISC data-dissemination agreement), Delaware (CourtConnect; Court of Chancery not included) and Arizona (apps.azcourts.gov/publicaccess, which has an official channel to request high-volume access) are the candidates; PartnerFacts will request written permission before any automated search. Federal courts are searched through CourtListener / RECAP.
None found in sources searched — SEC enforcement releases (index scan as of Oct 24, 2026, 2:50 AM ET) · state securities regulators: 48 regulators (FINRA, NASAA, 37 states) — crawled Oct 24, 2026, 8:48 AM ET
SEC enforcement searched: SEC litigation releases and administrative proceedings — respondent names in the sec.gov index titles (30,205 releases, 1995-09-19 to 2026-10-23); release text is read only to confirm a candidate. Names that appear only in the body of a release are not found. — Searched SEC litigation releases and administrative proceedings (1995→ / 2007→) (30,205 records as of Oct 24, 2026, 2:50 AM ET) — nothing matched Kush Parmar..
State securities regulators: Securities regulators searched (64,910 actions): FINRA (38,350 actions, 1995–2026), NASAA (31 actions, 2000–2026; listing starts 1997), AK Division of Banking and Securities (273 actions, 1971–2025), AL Securities Commission (880 actions, 2001–2026), AR Securities Department (1,305 actions, 1998–2026), AZ Corporation Commission Securities Division (411 actions, 2017–2026), CA DFPI (25 actions, 2007–2024; listing starts 2002 — 16 of 12,159 DFPI respondent pages read so far; sponsor-name matches are read first), CO Division of Securities (731 actions, 2001–2026; older years from the Internet Archive (snapshot of 2026-05-02)), CT Department of Banking Securities Division (940 actions, 2006–2026; older years from the Internet Archive (snapshot of 2026-04-22)), DC DISB Securities Bureau (25 actions, 2012–2026), DE DOJ Investor Protection Unit (257 actions, 1987–2026), FL Office of Financial Regulation (49 actions, 2018–2026), GA Secretary of State Securities Division (65 actions, 2015–2026; listing starts 2012), HI DCCA Securities Enforcement Branch (26 actions, 2012–2026), ID Department of Finance Securities Bureau (663 actions, 1994–2026), IL Secretary of State Securities Department (4,122 actions, 2003–2023), KS Insurance Department Securities Division (58 actions), KY Department of Financial Institutions (342 actions, 2005–2026), LA Office of Financial Institutions Securities Division (13 actions, 2010–2025; listing starts 2008), MA Secretary of the Commonwealth Securities Division (125 actions, 2012–2025; live site blocks automated access — loaded from the Internet Archive snapshot of 2026-02-04), MD Attorney General Securities Division (1,054 actions, 2004–2026), ME Office of Securities (539 actions, 2000–2026), MI LARA Corporations, Securities & Commercial Licensing Bureau (201 actions), MO Secretary of State Securities Division (919 actions, 1998–2026), MS Secretary of State Securities Division (209 actions, 1995–2026), MT Commissioner of Securities and Insurance (597 actions, 2000–2026), NC Secretary of State Securities Division (265 actions, 2004–2024), ND Securities Department (711 actions, 1990–2026; the regulator no longer publishes this list live — loaded from the Internet Archive snapshot of 2026-01-06), NH Bureau of Securities Regulation (402 actions, 2002–2026), NM Regulation and Licensing Department Securities Division (90 actions, 2010–2025), NV Secretary of State Securities Division (118 actions, 2018–2026), NY Attorney General Investor Protection Bureau (44 actions, 2012–2026), OH Division of Securities (327 actions, 1993–2006), OK Department of Securities (2,531 actions, 1998–2026), OR Division of Financial Regulation (589 actions, 1988–2026), PA Department of Banking and Securities (1,448 actions, 2008–2024; the regulator no longer publishes this list live — loaded from the Internet Archive snapshot of 2024-08-09), RI DBR Securities Division (98 actions, 2005–2025), SC Attorney General Securities Division (540 actions, 2006–2026), SD Division of Insurance – Securities Regulation (106 actions, 2017–2026), TN Department of Commerce and Insurance Securities Division (405 actions, 1992–2026), TX State Securities Board (936 actions, 1999–2026), UT Division of Securities (772 actions, 2000–2026; older years from the Internet Archive (snapshot of 2010-05-27)), VT DFR Securities Division (137 actions, 2010–2026), WA DFI (2,039 actions, 2001–2026), WI DFI Division of Securities (1,072 actions, 1998–2026), WV Securities Commission (State Auditor) (64 actions), WY Secretary of State Compliance Division (6 actions, 2016–2024) — last crawled Oct 24, 2026, 8:48 AM ET. No machine-readable public listing today for IA, IN, MN, NE, NJ, VA (see docs/state-regulators.md).
None found in sources searched — federal bankruptcy courts (CourtListener / RECAP), checked Oct 24, 2026
Sources searched: Federal bankruptcy courts via CourtListener / RECAP archive (federal district courts, federal bankruptcy courts). State courts: not covered (one-tap state court links under Look further). PACER: not searched (RECAP only). · Last checked Oct 24, 2026, 2:29 AM ET.
State courts: not covered (one-tap state court links under Look further). No state offers a lawful automated statewide source PartnerFacts can use today. Texas (re:SearchTX) terms prohibit storing results in a database open to third parties; New York (WebCivil) and Massachusetts (MassCourts) require a browser check that blocks scripted queries; California has no statewide index (58 county portals; Rule of Court 2.503 grants name-based access case by case); Florida, Utah and Illinois offer paid or partial access whose terms for automated use are unverified. Washington (dw.courts.wa.gov; bulk index reports under a JISC data-dissemination agreement), Delaware (CourtConnect; Court of Chancery not included) and Arizona (apps.azcourts.gov/publicaccess, which has an official channel to request high-volume access) are the candidates; PartnerFacts will request written permission before any automated search. Federal courts are searched through CourtListener / RECAP.
Comparisons cover issuers and sponsor groups — see the issuer pages under Deals
17 differences found between the filings for Kush Parmar — 1 worth asking about (compared 40 filings on Oct 24, 2026)
United States Bankruptcy Court, D. New Jersey docket "PNC Bank v. Litchman" filed Oct 23, 2000, closed Feb 27, 2002. Manuel Litchman (listed on the same filings) is listed as Defendant ("Litchman"). Our match estimate: 70%.
What this means A bankruptcy filing was found. Many are old or personal and have nothing to do with the deal — but ask what it was and when it closed.
The Sep 6, 2016 Form D reports $4,000,000 sold and $468,593 of the proceeds used for payments to officers, directors or promoters (marked as an estimate). Issuer's note: "Proceeds to be used for general working capital purposes, including the payment of compensation to certain of the directors and officers of the corporation listed as Related Persons in Item 3.".
What this means The filing reports how much of the money raised was paid to insiders. Over 10% is high for most deals. Ask what it paid for.
5AM Opportunities II, L.P. (last filing Mar 24, 2021; $0 sold of $300,000,000); 5AM Ventures VII, L.P. (last filing Mar 24, 2021; $0 sold of $450,000,000); 5AM Opportunities I, L.P. (last filing Oct 4, 2018; $0 sold of $150,000,000); 5AM Ventures VI, L.P. (last filing Oct 4, 2018; $0 sold of $350,000,000); Arvinas, Inc. (last filing Jul 16, 2013; $3,511,667 sold of $15,050,003). Each has no filing in more than two years and reported under half its target sold.
What this means An issuer whose last filing is more than two years old and reported under half its target sold. The raise may have closed early or quietly stopped. Ask what happened to each.
Form D filed 17 days after the first sale — Ensoma, Inc. · Form D filed 17 days after the first sale — Rallybio Corp · Form D filed 17 days after the first sale — Akouos, Inc. · Form D filed 16 days after the first sale — Audentes Therapeutics, Inc. · Form D filed 33 days after the first sale — Audentes Therapeutics, Inc.
What this means Late notices are common and carry no penalty by themselves. A pattern of late paperwork is worth asking the sponsor about.
No amendment in the last 12 months on an offering that may still be open — Ensoma, Inc. (latest filing Feb 19, 2021) · No amendment in the last 12 months on an offering that may still be open — Entrada Therapeutics, Inc. (latest filing Dec 26, 2019) · No amendment in the last 12 months on an offering that may still be open — Akouos, Inc. (latest filing Aug 1, 2018) · No amendment in the last 12 months on an offering that may still be open — Entrada Therapeutics, Inc. (latest filing Nov 10, 2016) · No amendment in the last 12 months on an offering that may still be open — scPharmaceuticals Inc. (latest filing Sep 6, 2016) · and 4 more
What this means SEC rules expect a yearly amendment while an offering is still going. Ask the sponsor which of these raises have closed.
The Feb 19, 2021 filing lists Kush Parmar as executive officer, director; the Jan 9, 2023 Form D lists director.
What this means Roles on Form D are self-reported by the issuer. A change can mean a real change in who runs the company, or just a different box ticked. Ask who makes decisions today.
The Nov 10, 2016 filing lists Kush Parmar as executive officer, director; the Dec 26, 2018 Form D lists director.
What this means Roles on Form D are self-reported by the issuer. A change can mean a real change in who runs the company, or just a different box ticked. Ask who makes decisions today.
The Jan 6, 2016 filing lists Kush Parmar as executive officer, director; the Feb 16, 2017 Form D/A lists director.
What this means Roles on Form D are self-reported by the issuer. A change can mean a real change in who runs the company, or just a different box ticked. Ask who makes decisions today.
The Jan 9, 2023 filing says $79,000,469 offered; the May 23, 2023 Form D/A says $129,000,467.
What this means The target raise changed. Raising the cap is common when a deal grows; ask whether the extra money has the same terms and use.
The Apr 13, 2020 filing says $130,000,000 offered; the May 29, 2020 Form D/A says $145,204,965.
What this means The target raise changed. Raising the cap is common when a deal grows; ask whether the extra money has the same terms and use.
The Jan 6, 2016 filing says $23,068,876 offered; the Feb 16, 2017 Form D/A says $43,568,874.
What this means The target raise changed. Raising the cap is common when a deal grows; ask whether the extra money has the same terms and use.
listed as "Kush Parmar" on 31 filings (from Jul 16, 2013), and "Kush M. Parmar" on 9 filings (from Mar 24, 2021).
What this means Same person, written differently — a middle name or suffix left off, or spelled another way. It is normal, but check that the full legal name matches your subscription documents.
"Other Health Care" (Apr 13, 2020 to May 29, 2020); then "Pharmaceuticals" (Apr 22, 2024).
What this means The issuer described its business differently on different forms. Often it is just a different box ticked; sometimes the deal itself changed. Ask which business your money is in.
"Pharmaceuticals" (Nov 10, 2016 to Dec 26, 2019); then "Biotechnology" (Apr 13, 2021).
What this means The issuer described its business differently on different forms. Often it is just a different box ticked; sometimes the deal itself changed. Ask which business your money is in.
"Biotechnology" (Apr 7, 2014); then "Pharmaceuticals" (Feb 4, 2016 to Jan 6, 2017).
What this means The issuer described its business differently on different forms. Often it is just a different box ticked; sometimes the deal itself changed. Ask which business your money is in.
Address moved from New York, NY to New Haven, CT — ARVINAS, INC. · Address moved from Brookline, MA to Boston, MA — Akouos, Inc. · Address moved from New Haven, CT to New York, NY — ARVINAS, INC. · Address moved from Boston, MA to Bedford, MA — Homology Medicines, Inc. · Address moved from Boston, MA to Lexington, MA — scPharmaceuticals Inc.
What this means Businesses move. If you were told one city and the forms say another, ask which is current.
MA on 21 filings (Jul 16, 2013 to May 23, 2023); CA on 15 filings (Dec 24, 2014 to Dec 23, 2025); CT on 4 filings (Jul 19, 2019 to Apr 22, 2024).
What this means The address on a Form D is usually the company's, not the person's home, so this often just reflects different companies. It can also mean a move. Nothing wrong by itself.
What is compared: every Form D and D/A we hold for this subject, side by side — filing dates vs. first-sale dates (the 15-day rule), amendment timing on open offerings (the yearly-amendment expectation), amounts sold, investor counts, offering amounts and minimums across amendments, industry and size bands, addresses, how each person's name and role is written, paid sellers' CRD numbers, and (for groups) where the member companies were formed and sit. Everything is as filed by the issuer; the SEC does not check it. Differences are common and usually have ordinary explanations — we show both values, the dates, and the source so you can ask. As of Oct 24, 2026.
0 of 32 offerings report sales commissions; 0 report finder's fees; 3 report proceeds to related persons totalling $4,023,346. (includes amounts the issuer reported as estimates)
| Offering (latest filing) | Sales commissions | Finder's fees | To insiders | Paid to sell it | Source |
|---|---|---|---|---|---|
| Dec 23, 2025 D/A 5AM Opportunities, L.P. File 021-533042 | $0 | $0 | $0 The Issuer charges a management fee that is described in the Issuer's offering documents. | None listed on this filing | EDGAR ↗ |
| Dec 23, 2025 D/A 5AM Opportunities Offshore, L.P. File 021-533043 | $0 | $0 | $0 The Issuer charges a management fee that is described in the Issuer's offering documents. | None listed on this filing | EDGAR ↗ |
| Apr 22, 2024 D Rallybio Corp File 021-511203 | $0 | $0 | $0 | None listed on this filing | EDGAR ↗ |
| May 23, 2023 D/A Ensoma, Inc. File 021-470026 | $0 | $0 | $0 | None listed on this filing | EDGAR ↗ |
| Apr 13, 2021 D Entrada Therapeutics, Inc. File 021-395485 | $0 | $0 | $0 | None listed on this filing | EDGAR ↗ |
| Mar 24, 2021 D 5AM Opportunities II, L.P. File 021-393252 | $0 | $0 | $0 The Issuer is obligated to pay a management fee to the General Partner (or an affiliate thereof). | None listed on this filing | EDGAR ↗ |
| Mar 24, 2021 D 5AM Ventures VII, L.P. File 021-393254 | $0 | $0 | $0 The Issuer is obligated to pay a management fee to the General Partner (or an affiliate thereof). | None listed on this filing | EDGAR ↗ |
| Feb 19, 2021 D Ensoma, Inc. File 021-389985 | $0 | $0 | $0 | None listed on this filing | EDGAR ↗ |
| Jul 10, 2020 D Vor Biopharma Inc. File 021-370729 | $0 | $0 | $0 | None listed on this filing | EDGAR ↗ |
| May 29, 2020 D/A Rallybio Corp File 021-364823 | $0 | $0 | $0 (est.) | None listed on this filing | EDGAR ↗ |
| Mar 3, 2020 D Akouos, Inc. File 021-361803 | $0 | $0 | $0 | None listed on this filing | EDGAR ↗ |
| Dec 26, 2019 D/A Entrada Therapeutics, Inc. File 021-328899 | $0 | $0 | $3,382,953 (est.) The above figure is an estimate of payments for services in the ordinary course made in 2019 and expected to be made over the course of 2020. | None listed on this filing | EDGAR ↗ |
| Jul 19, 2019 D ARVINAS, INC. File 021-344713 | $0 | $0 | $0 | None listed on this filing | EDGAR ↗ |
| Oct 4, 2018 D/A 5AM Opportunities I, L.P. File 021-322841 | $0 | $0 | $0 The Issuer is obligated to pay a management fee to the General Partner (or an affiliate thereof). | None listed on this filing | EDGAR ↗ |
| Oct 4, 2018 D/A 5AM Ventures VI, L.P. File 021-322844 | $0 | $0 | $0 The Issuer is obligated to pay a management fee to the General Partner (or an affiliate thereof). | None listed on this filing | EDGAR ↗ |
| Aug 1, 2018 D Akouos, Inc. File 021-318301 | $0 | $0 | $0 | None listed on this filing | EDGAR ↗ |
| Apr 5, 2018 D ARVINAS, INC. File 021-309449 | $0 | $0 | $0 No payments other than ordinary course employment compensation is being paid to officers or managers. | None listed on this filing | EDGAR ↗ |
| Nov 13, 2017 D Akouos, Inc. File 021-298512 | $0 | $0 | $0 | None listed on this filing | EDGAR ↗ |
| Aug 10, 2017 D Homology Medicines, Inc. File 021-292496 | $0 | $0 | $0 | None listed on this filing | EDGAR ↗ |
| Feb 16, 2017 D/A Homology Medicines, Inc. File 021-254611 | $0 | $0 | $0 | None listed on this filing | EDGAR ↗ |
| Jan 6, 2017 D scPharmaceuticals Inc. File 021-277857 | $0 | $0 | $0 | None listed on this filing | EDGAR ↗ |
| Nov 10, 2016 D Entrada Therapeutics, Inc. File 021-274261 | $0 | $0 | $0 | None listed on this filing | EDGAR ↗ |
| Sep 6, 2016 D scPharmaceuticals Inc. File 021-270107 | $0 | $0 | $0 | None listed on this filing | EDGAR ↗ |
| Sep 6, 2016 D scPharmaceuticals Inc. File 021-270108 | $0 | $0 | $468,593 (est.) Proceeds to be used for general working capital purposes, including the payment of compensation to certain of the directors and officers of the corporation listed as Related Persons in Item 3. | None listed on this filing | EDGAR ↗ |
| May 27, 2016 D 5AM Ventures V, L.P. File 021-264004 | $0 | $0 | $0 The Issuer is obligated to pay a management fee to the General Partner (or an affiliate thereof). | None listed on this filing | EDGAR ↗ |
| Feb 4, 2016 D scPharmaceuticals Inc. File 021-256791 | $0 | $0 | $171,800 (est.) Proceeds to be used for general working capital purposes, including the payment of compensation to certain of the directors and officers of the corporation listed as Related Persons in Item 3. | None listed on this filing | EDGAR ↗ |
| Oct 23, 2015 D ARVINAS, INC. File 021-249974 | $0 | $0 | $0 No payments other than ordinary course employment compensation is being paid to officers or directors. | None listed on this filing | EDGAR ↗ |
| Oct 22, 2015 D Audentes Therapeutics, Inc. File 021-249874 | $0 | $0 | $0 | None listed on this filing | EDGAR ↗ |
| Sep 2, 2015 D Audentes Therapeutics, Inc. File 021-246838 | $0 | $0 | $0 | None listed on this filing | EDGAR ↗ |
| Dec 24, 2014 D Audentes Therapeutics, Inc. File 021-230835 | $0 | $0 | $0 | None listed on this filing | EDGAR ↗ |
| Apr 7, 2014 D scPharmaceuticals Inc. File 021-215061 | $0 | $0 | $0 | None listed on this filing | EDGAR ↗ |
| Jul 16, 2013 D Arvinas, Inc. File 021-199736 | $0 | $0 | $0 Certain officers or directors of the issuer who are also employees of the issuer will be paid their ordinary course compensation as a normal business expense from the proceeds of the offering, although such payments are not tied to offering proceeds. | None listed on this filing | EDGAR ↗ |
Counts come from Form D Items 12–15 on the filings in our index (latest filing per offering; one offering = one SEC file number; an amendment updates its offering rather than adding one). "To insiders" = gross proceeds used for payments to executive officers, directors or promoters. "—" = not reported on that filing. Amounts marked (est.) were reported as estimates. "Paid to sell it" = sales compensation recipients named on that filing (Item 12), each linked to FINRA BrokerCheck when a CRD number is reported.
Counted across every filing this person is listed on (latest filing per offering, per issuer).
Every issuer that named Kush Parmar on a Form D, newest first. A Form D is the notice a company files after it starts selling a private investment.
Raised $6.5M from 4 investors as of the latest filing. Kush is listed as executive officer on 2 filings for this deal.
Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Pooled Investment Fund / 506(b) (83,801 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.
Raised $25.2M from 18 investors as of the latest filing. Kush is listed as executive officer on 2 filings for this deal.
Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Pooled Investment Fund / 506(b) (83,801 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.
Raised $145.2M from 28 investors (100% of the $6.6M target) as of the latest filing. Kush is listed as director on 3 filings for this deal.
Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Pharmaceuticals / 506(b) (800 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.
Raised $129M from 22 investors (100% of the $129M target) as of the latest filing. Kush is listed as director, executive officer on 3 filings for this deal.
Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Biotechnology / 506(b) (3,253 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.
Raised $116.2M from 26 investors (100% of the $116.2M target) as of the latest filing. Kush is listed as director, executive officer on 4 filings for this deal.
Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Biotechnology / 506(b) (3,253 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.
No sales reported yet as of the latest filing. Kush is listed as director.
Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Pooled Investment Fund / 506(b) (83,801 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.
No sales reported yet as of the latest filing. Kush is listed as director.
Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Pooled Investment Fund / 506(b) (83,801 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.
Raised $110.1M from 33 investors (100% of the $110.1M target) as of the latest filing. Kush is listed as director.
Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Other / 506(b) (18,678 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.
Raised $105.1M from 33 investors (100% of the $105.1M target) as of the latest filing. Kush is listed as director on 3 filings for this deal.
Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Biotechnology / 506(b) (3,253 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.
Raised $55M from 22 investors (100% of the $32.5M target) as of the latest filing. Kush is listed as director on 3 filings for this deal.
Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Biotechnology / 506(b) (3,253 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.
No sales reported yet as of the latest filing. Kush is listed as director on 2 filings for this deal.
Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Pooled Investment Fund / 506(b) (83,801 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.
No sales reported yet as of the latest filing. Kush is listed as director on 2 filings for this deal.
Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Pooled Investment Fund / 506(b) (83,801 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.
Raised $83.5M from 19 investors (100% of the $83.5M target) as of the latest filing. Kush is listed as director, executive officer on 3 filings for this deal.
Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Pharmaceuticals / 506(b) (800 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.
Raised $47M from 15 investors (100% of the $47M target) as of the latest filing. Kush is listed as director on 5 filings for this deal.
Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Pharmaceuticals / 506(b) (800 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.
Raised $285M from 80 investors (100% of the $285M target) as of the latest filing. Kush is listed as director.
Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Pooled Investment Fund / 506(b) (83,801 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.
Raised $65M from 27 investors (100% of the $65M target) as of the latest filing. Kush is listed as director on 3 filings for this deal.
Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Biotechnology / 506(b) (3,253 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.
Raised $3.51M from 6 investors (23% of the $15.1M target) as of the latest filing. Kush is listed as director.
Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer.
Officers, directors, promoters and management entities named on the same filings, as of Oct 23, 2026, 5:45 PM ET. Showing the 40 with the most shared filings.
Listed on the same filings as Kush Parmar. Their page shows their other deals.
Listed on the same filings as Kush Parmar. Their page shows their other deals.
Listed on the same filings as Kush Parmar. Their page shows their other deals.
Listed on the same filings as Kush Parmar. Their page shows their other deals.
Listed on the same filings as Kush Parmar. Their page shows their other deals.
Listed on the same filings as Kush Parmar. Their page shows their other deals.
Listed on the same filings as Kush Parmar. Their page shows their other deals.
Andrew Schwab is on 29 issuers in total — a repeat sponsor. Their page lists every one.
Listed on the same filings as Kush Parmar. Their page shows their other deals.
Mette Kirstine Agger is on 5 issuers in total — a repeat sponsor. Their page lists every one.
Tim Shannon is on 5 issuers in total — a repeat sponsor. Their page lists every one.
Jonathan T. Silverstein is on 33 issuers in total — a repeat sponsor. Their page lists every one.
Listed on the same filings as Kush Parmar. Their page shows their other deals.
Listed on the same filings as Kush Parmar. Their page shows their other deals.
Listed on the same filings as Kush Parmar. Their page shows their other deals.
Listed on the same filings as Kush Parmar. Their page shows their other deals.
Louis Tartaglia is on 5 issuers in total — a repeat sponsor. Their page lists every one.
Sean Cassidy is on 6 issuers in total — a repeat sponsor. Their page lists every one.
Liam Ratcliffe is on 11 issuers in total — a repeat sponsor. Their page lists every one.
Jonathan Leff is on 13 issuers in total — a repeat sponsor. Their page lists every one.
Listed on the same filings as Kush Parmar. Their page shows their other deals.
Thomas Woiwode is on 25 issuers in total — a repeat sponsor. Their page lists every one.
Listed on the same filings as Kush Parmar. Their page shows their other deals.
Listed on the same filings as Kush Parmar. Their page shows their other deals.
Ed Mathers is on 13 issuers in total — a repeat sponsor. Their page lists every one.
Andrew Levin is on 21 issuers in total — a repeat sponsor. Their page lists every one.
Steven Gillis is on 30 issuers in total — a repeat sponsor. Their page lists every one.
STEPHEN KNIGHT is on 9 issuers in total — a repeat sponsor. Their page lists every one.
Louis Lange is on 9 issuers in total — a repeat sponsor. Their page lists every one.
One team, 2 deal companies. Kush Parmar is listed on 2 of them.
Issuers are grouped when their Form D filings share related persons, a management entity or a business address (automatic match from the filings). "Listed" marks the issuers that name Kush Parmar.
One team, 2 deal companies. Kush Parmar is listed on 2 of them.
Issuers are grouped when their Form D filings share related persons, a management entity or a business address (automatic match from the filings). "Listed" marks the issuers that name Kush Parmar.
A shared address can mean the same team, a shared office building or a registered agent. It is a lead, not a conclusion.
Individuals are not matched to business registrations — registries list companies, and a name alone is not enough to tie a person to one. Officers and managers appear by name inside each matched company's record on the issuer pages. Registries searched: AL (Alabama Secretary of State — Business Entity Records (arc-sos.state.al.us), searched by issuer name, data as of Oct 24, 2026); CO (Colorado Secretary of State — Business Entities in Colorado (data.colorado.gov), data as of Oct 23, 2026); CT (Connecticut Secretary of the State — Business Registry (data.ct.gov), data as of Oct 24, 2026); FL (Florida Department of State, Division of Corporations — quarterly corporate data file (Sunbiz), data as of Oct 7, 2026); NY (New York Department of State — Corporations and Other Entities (data.ny.gov: All Filings + Active Corporations), data as of Oct 20, 2026); OR (Oregon Secretary of State — Active Businesses, All (data.oregon.gov), data as of Oct 20, 2026); PA (Pennsylvania Department of State — Registered Businesses, Current (data.pa.gov), data as of Oct 6, 2026); TX (Texas Comptroller — Active Franchise Taxpayers incl. Secretary of State file data (data.texas.gov), data as of Oct 24, 2026). Registries of other states have not been searched: many publish no bulk file and require a CAPTCHA or bot challenge on their search page, which we do not bypass (Delaware, for example, offers no public bulk file).
None of the 17 issuers this person is listed on appears in Form ADV (searched 24,962 advisers as of Oct 2, 2026). A person is never an adviser firm; Form ADV is checked for the issuers and the management companies they are listed with.
Searched SEC Regulation A Data Sets (Forms 1-A, 1-K, 1-Z; 2015 Q2 → 2026 Q3); SEC Crowdfunding Offerings Data Sets (Form C family; 2016 Q2 → 2026 Q3); EDGAR form index for 2026 Q3 → 2026 Q4 (51,358 records as of Oct 23, 2026, 8:41 PM ET) — nothing matched this name.
Property records are matched to companies only, never to individuals, so none are matched to Kush Parmar by design. Searched property records in Hillsborough County FL (Clerk recorded-document index Oct 14, 2026 to Oct 15, 2026 + FL DOR 2026 ownership roll), Miami-Dade County FL (FL DOR 2026 ownership roll), Harris County TX (HCAD 2026 ownership roll), Dallas County TX (DCAD 2026 ownership roll), New York City ACRIS documents and PLUTO ownership rows already retrieved for other issuers, Cook County IL sale and ownership rows already retrieved for other issuers (814,874 records as of Oct 23, 2026, 8:59 PM ET) for the 17 issuers this person is listed on — nothing matched.
Websites and social links of the issuers Kush Parmar is listed on: none on file. No website or social profile named in 5AM Ventures V, L.P.'s SEC filings (Form C, Reg A, Form ADV; checked Oct 24, 2026). Web search for this name: #286,620 of 374,652 in line (1,386 issuers searched so far). One-tap searches: Look further ↓
One-tap searches on sites we do not index ourselves, with the name pre-filled (Menlo Park, CA). Each opens in a new tab; what you find there is not verified by PartnerFacts.
No corrections have been requested for this page.
Free. Logged with status: received → under review → fixed / confirmed with source.
If this is you or your firm, add a sourced explanation next to any fact. Reviewed before publishing.
Members get an email when Kush Parmar appears on a new Form D, or when a court case or SEC action is matched to them. See plans →
